^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor) + carfilzomib (Proteasome inhibitor) |
| Direction: | Sensitive |
Evidence:
Title:
carfilzomib (Kyprolis) is accepted for restricted use within NHSScotland
Published date:
09/04/2020
Excerpt:
carfilzomib (Kyprolis) is accepted for restricted use within NHSScotland...in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Source:
Published date:
08/20/2020
Excerpt:
Kyprolis is a proteasome inhibitor that is indicated...for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with...Lenalidomide and dexamethasone...Dexamethasone...Daratumumab and dexamethasone.
Source:
Published date:
11/19/2015
Excerpt:
Kyprolis in combination with either lenalidomide and dexamethasone or dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Source:
Title:
Triple therapy recommended by NICE for patients with multiple myeloma
Published date:
03/22/2021
Excerpt:
A new second line triple therapy is to be offered to NHS patients in England with multiple myeloma after NICE recommended its use...Carfilzomib with dexamethasone and lenalidomide could be offered to around 2,000 patients with multiple myeloma who have had at least one previous therapy, which include bortezomib.
Source:
Excerpt:
…the NCCN Panel has included the carfilzomib, lenalidomide, and dexamethasone regimen as an option for primary treatment of transplant-eligible patients with MM.
Source:
Title:
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial
Published date:
01/12/2023
Excerpt:
With a median follow-up of 33·8 months (IQR 20·9-42·9), median progression-free survival was 59·1 months (95% CI 54·8-not estimable) in the carfilzomib, lenalidomide, and dexamethasone group versus 41·4 months (33·2-65·4) in the lenalidomide group (hazard ratio 0·51 [95% CI 0·31-0·86]; p=0·012)...This interim analysis provides support for considering carfilzomib, lenalidomide, and dexamethasone therapy in patients with newly diagnosed multiple myeloma...
DOI:
10.1016/S1470-2045(22)00738-0
Trial ID:
Source:
Title:
Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR
Published date:
10/16/2020
Excerpt:
These post hoc exploratory analyses of extended follow-up data from the ASPIRE and ENDEAVOR pivotal phase 3 studies of carfilzomib in RRMM showed that best responses (≥CR) were achieved by 31.8 and 13.0% of patients treated with KRd and Kd, respectively...Best responders presented a longer exposure to carfilzomib and had longer median PFS and OS than patients who achieved VGPR/PR in both studies.
DOI:
10.1038/s41375-020-01049-5
Trial ID:
